New Mexico Clinical Trials Report — June 2026

For New Mexicans considering participation in clinical research, June 2026 presents both urgent opportunities and significant new avenues for contribution. A total of 23 clinical trials across the state are slated to conclude enrollment within the next 90 days, meaning time is rapidly running out to join these studies. This critical window includes 6 trials that are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various conditions, from metabolic health to mental health and oncology, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Hematologic tests
• Obesity
• Autism spectrum disorder
• Breast cancer
• Dietary carcinogenesis
• Cancer
• Bipolar disorder I or II with a major depressive episode
• Cervical carcinoma
• Chronic granulomatous disease (CGD)
• COVID-19

Major Drug Trials Launch for Migraine and Type 2 Diabetes

This month, New Mexico welcomes 5 new clinical trials, a slight increase from the 4 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like migraine and type 2 diabetes.

• Kallyope Inc. is sponsoring two important Phase 3 trials for migraine treatment. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," is a double-blind, randomized study aiming for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo. Complementing this, NCT07674654 is a "Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," targeting 1,000 participants to assess the safety and tolerability of intermittent use of elismetrep over an extended period.
• AstraZeneca is leading two substantial Phase 3 trials for type 2 diabetes. NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide," aims to enroll 1,200 participants. This study will evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk. Additionally, NCT07662135 is a "Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin," planning for 900 participants to assess elecoglipron in T2DM patients with impaired renal function already on dapagliflozin.
• For individuals with opioid use disorder, Montefiore Medical Center is sponsoring NCT07631598, "Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses." This study, involving 512 participants, investigates whether offering buprenorphine treatment directly at syringe service programs (SSPs) improves treatment initiation and retention compared to traditional referrals.

New Research Opportunities Across Conditions and Interventions

The 5 new trials opening this month in New Mexico cover a focused range of health conditions, with a strong emphasis on metabolic health and addiction treatment. The conditions addressed by these new studies include:

• Type 2 diabetes mellitus (2 trials)
• Migraine (1 trial)
• Opioid use disorder (1 trial)
• Acute migraine (1 trial)
• Opioid use disorder, severe (1 trial)
• Type 2 diabetes with chronic kidney disease (1 trial)
• Opioid use disorder, moderate (1 trial)

In terms of intervention types, drug trials lead the way, accounting for 4 of the new studies. A behavioral intervention trial and another "other" type of study also launched, diversifying the research landscape.

Geographic Reach: Albuquerque Leads New Trial Openings

New Mexico's clinical research landscape is active, with 380 clinical trials currently recruiting across 13 cities and 197 research sites statewide. This month, the majority of new research initiatives are concentrated in the state's largest city, Albuquerque, which saw 4 new trials open. Additionally, the city of Roswell welcomed 1 new trial, expanding access to cutting-edge research in another part of the state.

Healthy Volunteers and Diverse Demographics Welcome

For individuals without a specific medical condition, there are opportunities to contribute to medical science. Of the 5 new trials launched this month, 1 is actively seeking healthy volunteers. Statewide, a total of 32 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research. Remember, 6 of these healthy volunteer trials are closing soon, so prompt action is encouraged.

Clinical trials in New Mexico are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 5 include older adults, ensuring that research benefits this important demographic. No new trials this month are exclusively for children, females, or males. Industry sponsors continue to drive significant research efforts, with 4 new trials sponsored by pharmaceutical companies such as AstraZeneca and Kallyope Inc., alongside 1 study from an academic institution.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments and interventions for a broad spectrum of health challenges across New Mexico.